Travaux scientifiques

Prof. Dr. Saadettin Kılıçkap

479 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil
  1. Determining the Current Situation of Geriatric Oncology in Turkey: A Survey of Medical Oncologists

    Journal of Oncological Sciences, 2021

    DOI 10.37047/jos.2020-80824 Texte intégral en libre accèsSource : OpenAlex

  2. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.11.013 PMID 34861371 133 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  3. Initiation of Chemosaturation With Percutaneous Hepatic Perfusion Program in Interventional Radiology Department

    Cureus, 2021

    DOI 10.7759/cureus.17880 PMID 34660079 Texte intégral en libre accèsSource : OpenAlex

  4. Thirty-day mortality rates after immunotherapy initiation

    Immunotherapy, 2021

    DOI 10.2217/imt-2021-0082 PMID 34676791 2 citations (Europe PMC) Source : Europe PMC

  5. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab

    International Journal of Clinical Oncology, 2021

    DOI 10.1007/s10147-021-01936-6 PMID 34023933 14 citations (Europe PMC) Source : ORCID

  6. Merkel cell carcinoma in Turkey: A multicentric study

    Journal of Cancer Research and Therapeutics, 2021

    DOI 10.4103/jcrt.jcrt_950_19 PMID 34916389 3 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  7. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune checkpoint inhibitors

    Biomarkers in medicine, 2021

    DOI 10.2217/bmm-2020-0674 PMID 34397271 8 citations (Europe PMC) Source : Europe PMC

  8. Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review

    Frontiers in Oncology, 2021

    DOI 10.3389/fonc.2021.759108 PMID 34804957 25 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  9. Assessment of adherence to cancer-associated venous thromboembolism guideline and pharmacist’s impact on anticoagulant therapy

    Supportive Care in Cancer, 2021

    DOI 10.1007/s00520-020-05669-6 PMID 32776163 9 citations (Europe PMC) Source : ORCID

  10. Blood based biomarkers as predictive factors for hyperprogression

    Research Square, 2021

    DOI 10.21203/rs.3.rs-991928/v1 Texte intégral en libre accèsSource : ORCID

  11. Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report

    Journal of Oncology Pharmacy Practice, 2021

    DOI 10.1177/1078155220965677 PMID 33070764 7 citations (Europe PMC) Source : ORCID

  12. Clinical features and outcomes of COVID-19 in patients with solid tumors: Turkish National Registry Data

    International Journal of Cancer, 2021

    DOI 10.1002/ijc.33426 PMID 33284987 16 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  13. Comparison of respiratory muscle strength and endurance, maximal oxygen consumption, and fatigue in colorectal cancer survivors with healthy adults

    Supportive Care in Cancer, 2021

    DOI 10.1007/s00520-020-05963-3 PMID 33392768 3 citations (Europe PMC) Source : ORCID

  14. Comparison of response and survival of first-line crizotinib therapy according to EML-4 ALK fusion variants in advanced non-small cell lung cancer patients: A Turkish Oncology Group study

    Journal of B.U.ON., 2021

    Source : ORCID

  15. Efficacy analyses of axitinib and nivolumab in metastatic renal cell carcinoma after failure of targeted therapy: Which is better?

    Journal of B.U.ON., 2021

    PMID 34761618 2 citations (OpenAlex) Source : ORCID

  16. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors

    Supportive Care in Cancer, 2021

    DOI 10.1007/s00520-020-05702-8 PMID 32851486 10 citations (Europe PMC) Source : ORCID

  17. PILE: a candidate prognostic score in cancer patients treated with immunotherapy

    Clinical and Translational Oncology, 2021

    DOI 10.1007/s12094-021-02560-6 PMID 33586122 24 citations (Europe PMC) Source : ORCID

  18. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy

    Supportive Care in Cancer, 2021

    DOI 10.1007/s00520-021-06139-3 PMID 33709186 20 citations (Europe PMC) Source : ORCID

  19. Same disease, different approaches: A report on six lymphoma cases with extranodal marginal zones in rare sites

    Journal of Oncological Science, 2021

    DOI 10.37047/jos.2020-79452 1 citation (OpenAlex) Texte intégral en libre accèsSource : ORCID

  20. The Efficacy and Safety of Treatment Regimens Used in the First-Line Setting in Metastatic Pancreatic Cancer Patients: A Multicenter Real-Life Study

    Research Square, 2021

    DOI 10.21203/rs.3.rs-747492/v1 Texte intégral en libre accèsSource : ORCID

  21. The Relationship Between Systemic Immune Inflammation Index and Treatment Response in Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors: Results from The Turkish Oncology Group Kidney Cancer Consortium Database

    Research Square, 2021

    DOI 10.21203/rs.3.rs-1101225/v1 Texte intégral en libre accèsSource : ORCID

  22. The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study

    Current Problems in Cancer, 2021

    DOI 10.1016/j.currproblcancer.2021.100760 PMID 34130864 16 citations (Europe PMC) Source : ORCID

  23. The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme

    Future Oncology, 2021

    DOI 10.2217/fon-2021-0681 PMID 34409854 13 citations (Europe PMC) Source : ORCID

  24. The effect of the COVID-19 pandemic on routine adult vaccination in cancer patients

    Medical Oncology, 2021

    DOI 10.1007/s12032-021-01512-y PMID 33891205 3 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  25. The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study

    Journal of B.U.ON., 2021

    Source : ORCID

  26. What’s the difference between hyperprogressive disease and progressive disease for patients with treated immune checkpoint inhibitors?

    Research Square, 2021

    DOI 10.21203/rs.3.rs-1184111/v1 Texte intégral en libre accèsSource : ORCID

  27. 456P Prognostic and predictive value of tumor-infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.08.977 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  28. 976P The 30-day mortality rate after first cycle of immunotherapy

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.08.1360 Texte intégral en libre accèsSource : OpenAlex

  29. Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality

    BMJ Supportive & Palliative Care, 2021

    DOI 10.1136/bmjspcare-2021-003301 PMID 34711656 43 citations (OpenAlex) Source : OpenAlex

  30. MO368THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY

    Nephrology Dialysis Transplantation, 2021

    DOI 10.1093/ndt/gfab082.0022 1 citation (OpenAlex) Source : OpenAlex

  31. OA01.03 Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC

    Journal of Thoracic Oncology, 2021

    DOI 10.1016/j.jtho.2021.01.272 4 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  32. FP04.03 Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

    Journal of Thoracic Oncology, 2021

    DOI 10.1016/j.jtho.2021.08.217 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  33. Physiological Cost in Daily Life Activities in Lung Cancer

    European Respiratory Journal, 2021

    DOI 10.1183/13993003.congress-2021.pa762 Source : OpenAlex

  34. A comparison of respiratory muscle endurance, respiratory muscle endurance workload, and quality of life in low and high-fatigue colorectal cancer survivors

    European Respiratory Journal, 2021

    DOI 10.1183/13993003.congress-2021.pa1992 Source : OpenAlex

  35. 85P The association between diabetes and survival in patients treated with immunotherapy

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.10.103 Texte intégral en libre accèsSource : OpenAlex

  36. 38P The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.10.054 Texte intégral en libre accèsSource : OpenAlex

  37. Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer

    Tumori Journal, 2020

    DOI 10.1177/0300891620969823 PMID 33167790 4 citations (Europe PMC) Source : OpenAlex

  38. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

    Lung Cancer, 2020

    DOI 10.1016/j.lungcan.2020.07.022 PMID 32799090 30 citations (Europe PMC) Source : OpenAlex

  39. Neutrophil–lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)

    Journal of Oncology Pharmacy Practice, 2020

    DOI 10.1177/1078155219900908 PMID 32054412 9 citations (Europe PMC) Source : OpenAlex

  40. Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey.

    PubMed, 2020

    PMID 33099930 5 citations (Europe PMC) Source : OpenAlex

  41. Third-line Therapy for Metastatic Renal Cell Carcinoma and Its Effect on Quality of Life and Overall Survival: A National, Multicenter, Observational Study

    Journal of Oncological Sciences, 2020

    DOI 10.37047/jos.2020-75080 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  42. Multicenter real life expeMulticenter real life experience of biological agents in patients with metastatic colorectal cancerrience of biological agents in patients with metastatic colorectal cancer

    2020

    Source : OpenAlex

  43. Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey

    Bursa Uludag University - AVESIS, 2020

    Source : OpenAlex

  44. Prognostic value of the 2017 World Health Organization Classification System for gastric neuroendocrine tumors: A single-center experience

    The Turkish Journal of Gastroenterology, 2020

    DOI 10.5152/tjg.2020.18919 PMID 32141816 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  45. Factors affecting the response to Y-90 microsphere therapy in the cholangiocarcinoma patients

    La radiologia medica, 2020

    DOI 10.1007/s11547-020-01240-9 PMID 32594427 31 citations (Europe PMC) Source : OpenAlex

  46. Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences

    European Urology Focus, 2020

    DOI 10.1016/j.euf.2020.09.010 PMID 33008789 8 citations (Europe PMC) Source : ORCID

  47. Clinical impact of 68Ga-DOTATATE PET-CT imaging in patients with medullary thyroid cancer

    Annals of Nuclear Medicine, 2020

    DOI 10.1007/s12149-020-01494-3 PMID 32602032 21 citations (Europe PMC) Source : ORCID

  48. Complete responses to two different anti-PD1 agents in a metastatic melanoma patient

    Journal of Oncology Pharmacy Practice, 2020

    DOI 10.1177/1078155219858657 PMID 31256744 3 citations (Europe PMC) Source : ORCID

  49. Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer

    Journal of Oncology Pharmacy Practice, 2020

    DOI 10.1177/1078155219877234 PMID 31566114 10 citations (Europe PMC) Source : ORCID

  50. Docetaxel, cisplatin, and fluorouracil combination chemotherapy in neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma: A retrospective study

    Journal of Oncological Science, 2020

    DOI 10.37047/jos.2020-76836 1 citation (OpenAlex) Texte intégral en libre accèsSource : ORCID